Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Steven N Gallicchio

Ian M Bell

C Blair Zartman

Craig A Stump

Cory R Theberge

Mark E Fraley

Daniel Vincent Paone

Cheng Wang

Helen J Mitchell

Donnette D Staas

Anthony T Ginnetti

Harold G Selnick

Michael R Wood

Xufang Zhang

Heather E Stevenson

Joseph P Vacca

Xu-Fang Zhang

Theresa M Williams

Valentino J Stella

Douglas C Beshore

Blair C Zartman

Anthony Ginetti

Daniel V Paone

Anthony Ginnetti

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide azaindane CGRP receptor antagonists

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to compounds of Formula I: I (where A, A, B, B, B, B, D, D, J, K, T, U, V, W, X, Y, Z, R, R, R, R, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. 

Tricyclic anilide spirolactam CGRP receptor antagonists

Disclosed are prodrug compounds of formula (I) (wherein variables Rand Rare as described herein) which are analogues of an antagonist of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. 

Prodrugs of CGRP receptor antagonists

The present invention is directed to compounds of Formula I: (where variables A, A, B, J, K, m, n, R, R, Rand Rare as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Bicyclic anilide spirolactam CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, B, B, B, B, D, D, E, E, E, E, E, G, G, R, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirohydantoin tricyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, B, B, B, B, D, D, E, E, E, E, E, G, G, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirolactam tricyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, m, n, J, Q, R, E, E, E, R, R, R, R, Rand Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Substituted monocyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A, A, A, A, A, A, A, E, E, E, E, E, G, G, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spirolactam aryl CGRP receptor antagonists

The present invention is directed to compounds of Formula I: I (where A, A, B, B, B, B, D, D, T, U, V, W, X, Y, Z, R, R?, R, R, R, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. 

Growing community of inventors

Horsham, PA, United States of America

Steven N Gallicchio